Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
BDH INDUS. TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BDH INDUS. Mar-23 |
TEVA PHARMA Dec-13 |
BDH INDUS./ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 211 | 3,479 | - | |
Low | Rs | 93 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 129.3 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | 14.2 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | 15.2 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 109.18 | - | |
Avg Dividend yield | % | 2.6 | 3.4 | 78.4% | |
Book value per share (Unadj.) | Rs | 95.0 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 5.76 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.2 | 1.6 | 72.1% | |
Avg P/E ratio | x | 10.7 | 26.1 | 40.9% | |
P/CF ratio (eoy) | x | 10.0 | 11.4 | 87.7% | |
Price / Book Value ratio | x | 1.6 | 1.5 | 109.1% | |
Dividend payout | % | 28.1 | 87.5 | 32.1% | |
Avg Mkt Cap | Rs m | 874 | 2,756,220 | 0.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 70 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 745 | 1,692,969 | 0.0% | |
Other income | Rs m | 8 | 0 | - | |
Total revenues | Rs m | 753 | 1,692,969 | 0.0% | |
Gross profit | Rs m | 110 | 463,620 | 0.0% | |
Depreciation | Rs m | 6 | 136,844 | 0.0% | |
Interest | Rs m | 2 | 33,253 | 0.0% | |
Profit before tax | Rs m | 111 | 293,523 | 0.0% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | 29 | -3,584 | -0.8% | |
Profit after tax | Rs m | 82 | 105,758 | 0.1% | |
Gross profit margin | % | 14.7 | 27.4 | 53.7% | |
Effective tax rate | % | 25.9 | -1.2 | -2,118.6% | |
Net profit margin | % | 11.0 | 6.2 | 176.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 605 | 1,143,425 | 0.1% | |
Current liabilities | Rs m | 246 | 997,163 | 0.0% | |
Net working cap to sales | % | 48.2 | 8.6 | 557.6% | |
Current ratio | x | 2.5 | 1.1 | 214.3% | |
Inventory Days | Days | 3 | 91 | 2.8% | |
Debtors Days | Days | 816 | 96 | 850.6% | |
Net fixed assets | Rs m | 195 | 552,961 | 0.0% | |
Share capital | Rs m | 58 | 4,167 | 1.4% | |
Net worth | Rs m | 547 | 1,880,567 | 0.0% | |
Long term debt | Rs m | 0 | 865,653 | 0.0% | |
Total assets | Rs m | 800 | 3,868,976 | 0.0% | |
Interest coverage | x | 71.1 | 9.8 | 723.0% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.4 | 212.6% | |
Return on assets | % | 10.4 | 3.6 | 290.8% | |
Return on equity | % | 15.0 | 5.6 | 266.7% | |
Return on capital | % | 20.5 | 4.9 | 416.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 63 | 269,772 | 0.0% | |
From Investments | Rs m | 5 | -95,591 | -0.0% | |
From Financial Activity | Rs m | 4 | -323,609 | -0.0% | |
Net Cashflow | Rs m | 71 | -149,429 | -0.0% |
Compare BDH INDUS. With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare BDH INDUS. With: ALKEM LABORATORIES SUVEN LIFE SCIENCES PLETHICO PHARMA VIVIMED LABS BHARAT PARENTALS
Indian share markets continued the momentum as the session progressed and ended the higher.